Home  >  MEDTECH  > Nanosphere announces distribution and collaboration ...
May 18th, 2013
Nanosphere announces distribution and collaboration agreement with Hitachi high-technologies corporation
Nanosphere a leader in the development and commercialization of advanced molecular diagnostics systems, announced it has signed a distribution and collaboration agreement with Hitachi High-Technologies Corporation (Hitachi High-Tech).
Send to a friend

- Hitachi High-Technologies Corporation Provides Distribution Network to Market the Verigene System in Japan's High Growth Molecular Diagnostic Market
- Collaboration Leverages Each Companies' Advanced Design, Development and Manufacturing Expertise for Future Assays and Platforms

The agreement grants Hitachi High-Tech exclusive rights to market Nanosphere products in Japan. As well, the two companies intend to collaborate on assay and platform development.

The partnership plays a significant role in Nanosphere's global distribution strategy, as it expands the Company's product reach into one of the largest healthcare markets in the world.

"Nanosphere's portfolio of molecular diagnostics tests fits well with Japan's demand for rapid and accurate diagnostic tools to fight infections, enabling clinicians to target therapies potentially improving critical patient care and outcomes," said Kazuhiro Matsumura, Hitachi High-Tech's General Manager, Medical Systems Business Development Department, Strategic Planning Division, Science & Medical Systems Business Group. Mr. Matsumura added, "Nanosphere's rapid sample-to-result Verigene System meets the needs of Japan's health care providers who have been waiting for a molecular platform accessible to hospitals of all sizes."

"We are very pleased to be partnering with Hitachi High-Tech given their experience and reputation in both marketing and developing diagnostic products," said Michael McGarrity, Nanosphere's president and chief executive officer. "Hitachi High-Tech has a world class reputation for excellence and quality worldwide, and we jointly believe there is a considerable market and value creation opportunity that will be realized through this collaboration."

Benefits of Nanosphere's Growing Menu of Infectious Disease Products
The need for rapid, accurate and clinically actionable diagnostic results has been well defined in Europe and the USA with Nanosphere's broad menu of infectious disease tests:

- Gram-Positive Blood Culture test (BC-GP) to detect bacteria, including antibiotic resistance markers, that may cause bloodstream infections (510(k) cleared; CE Mark)
- Gram-Negative Blood Culture test (BC-GN) to detect Bacteria including antibiotic resistance markers, that may cause bloodstream infections (CE Mark)
- Respiratory Virus Plus test (RV+) to detect multiple respiratory viruses which cause respiratory tract infections (510(k) cleared; CE Mark)
- Clostridium difficile test (CDF) to detect potentially deadly C. difficile and identifies the 027 hypervirulent strain (510(k) cleared; CE Mark)
- Enteric Pathogens test (EP) to detect and multiple bacteria, viruses and toxin genes which cause gastrointestinal infections (In Clinical Trials). Nanosphere plans to commercialize the Enteric Pathogens    test in 2013 following receipt of the necessary regulatory approvals.

About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, for multiplexed infectious disease, genetic, and ultra-sensitive protein testing. This easy-to-use platform offers laboratories a convenient, simple, and cost-effective solution for highly sensitive nucleic acid and protein testing. Nanosphere is based in Northbrook, IL.

About Hitachi High-Technologies Corporation
Hitachi High-Technologies Corporation, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including Electronic Device Systems, Fine Technology Systems, Science & Medical Systems, Industrial & IT Systems, and Advanced Industrial Products. The company's consolidated sales for FY 2011 were more than $7.8 billion. For further information, please visit http://www.hitachi-hitec.com/global/.

More MEDTECH news

Sep 16th
Sep 16th
Sep 12th
Sep 9th
Sep 8th
©2007 Yole Developpement All rights reserved                  Disclaimer | Legal notice | To advertise
Yole Développement: Le Quartz, 75 cours Emile Zola, 69100 Villeurbanne, France. TEL: (33) 472 83 01 80 FAX: (33) 472 83 01 83 E-Mail: info @yole.fr